ATE556058T1 - 1-(2h)-isochinolonderivat - Google Patents

1-(2h)-isochinolonderivat

Info

Publication number
ATE556058T1
ATE556058T1 AT05709816T AT05709816T ATE556058T1 AT E556058 T1 ATE556058 T1 AT E556058T1 AT 05709816 T AT05709816 T AT 05709816T AT 05709816 T AT05709816 T AT 05709816T AT E556058 T1 ATE556058 T1 AT E556058T1
Authority
AT
Austria
Prior art keywords
substituted
hydrogen atom
group
atom
hetero ring
Prior art date
Application number
AT05709816T
Other languages
English (en)
Inventor
Kazuo Hattori
Satoshi Niizuma
Takehiro Okada
Hiroyuki Eda
Kenji Tatsuno
Miyuki Yoshida
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE556058T1 publication Critical patent/ATE556058T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05709816T 2004-02-06 2005-02-07 1-(2h)-isochinolonderivat ATE556058T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004030885 2004-02-06
PCT/JP2005/001764 WO2005075431A1 (ja) 2004-02-06 2005-02-07 1−(2h)−イソキノロン誘導体

Publications (1)

Publication Number Publication Date
ATE556058T1 true ATE556058T1 (de) 2012-05-15

Family

ID=34836016

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05709816T ATE556058T1 (de) 2004-02-06 2005-02-07 1-(2h)-isochinolonderivat

Country Status (6)

Country Link
US (1) US8143274B2 (de)
EP (1) EP1724262B1 (de)
JP (1) JP4938311B2 (de)
AT (1) ATE556058T1 (de)
TW (1) TW200536830A (de)
WO (1) WO2005075431A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846915B2 (en) * 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
TWI389897B (zh) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
WO2007016525A2 (en) * 2005-07-29 2007-02-08 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US8034829B2 (en) 2006-11-17 2011-10-11 Rexahn Pharmaceuticals, Inc. 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives and therapeutic use thereof
CN101595094B (zh) * 2006-12-27 2013-02-20 塞诺菲-安万特股份有限公司 环烷基胺取代的异喹诺酮衍生物
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
US8735391B2 (en) * 2008-09-26 2014-05-27 University Of Kansas Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods
US8420668B2 (en) 2008-11-28 2013-04-16 Chugai Seiyaku Kabushiki Kaisha 1-(2H)-isoquinolone derivative
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
CA2751892A1 (en) 2009-01-15 2010-07-22 Rutgers, The State University Of New Jersey Benzo [c] phenanthridines as antimicrobial agents
NZ617779A (en) 2009-03-18 2015-08-28 Resverlogix Corp Novel anti-inflammatory agents
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
CA2760526A1 (en) 2009-04-30 2010-11-04 Rutgers, The State University Of New Jersey Antimicrobial agents
CN101602725B (zh) * 2009-07-21 2012-07-11 浙江大学 六氢异喹啉酮类化合物的合成方法
CN102666540A (zh) * 2009-10-13 2012-09-12 Msd欧斯股份有限公司 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物
FR2956816B1 (fr) 2010-03-01 2012-05-18 Univ Joseph Fourier Utilisation de quinolones pour la preparation de medicaments, nouvelles quinolones et leur procede de synthese
US8933096B2 (en) 2010-06-09 2015-01-13 Rugers, The State University of New Jersey Antimicrobial agents
WO2011163610A2 (en) 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Antimicrobial agents
PT2773354T (pt) 2011-11-01 2019-07-17 Resverlogix Corp Formulações orais de libertação imediata para quinazolinonas substituídas
WO2013106756A2 (en) 2012-01-13 2013-07-18 Rutgers, The State University Of New Jersey Antimicrobial agents
RU2696572C2 (ru) 2012-03-07 2019-08-05 Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
EP2828245A1 (de) 2012-03-21 2015-01-28 Rutgers, The State University of New Jersey Antimikrobiotika
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. ブロモドメイン阻害剤としての新規複素環式化合物
EP2970143B1 (de) 2013-03-15 2022-11-09 Johnson Matthey Public Limited Company Verfahren zur herstellung von alkylestern aus 4-(5-(bis(2-hydroxyethyl)amino)-1-methyl-1h-benzo[d-]imidazol-2-yl-)buttersäure
CA2922469A1 (en) 2013-09-11 2015-03-19 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2015095446A1 (en) * 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
JP6917989B2 (ja) 2015-11-06 2021-08-11 ニューロクライン バイオサイエンシーズ,インコーポレイテッド 神経学的疾患を処置するためのムスカリン受容体4(m4)アンタゴニストとしての、n−[2−(1−ベンジルピペリジン−4−イル)エチル]−4−(ピラジン−2−イル)−ピペラジン−1−カルボキサミド誘導体および関連化合物
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
WO2017147316A1 (en) 2016-02-25 2017-08-31 Taxis Pharmaceuticals, Inc. Synthetic processes and intermediates
WO2018157857A1 (zh) * 2017-03-03 2018-09-07 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用
CN110891566B (zh) 2017-03-30 2023-12-19 塔克西斯医药股份有限公司 合成方法和合成中间体
EP4151627A1 (de) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Verbindungen zur behandlung von morbus huntington
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
US12030867B2 (en) 2018-05-30 2024-07-09 University Of Notre Dame Du Lac Hsp90β selective inhibitors
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
US12486250B2 (en) 2019-12-06 2025-12-02 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
GB2634228A (en) * 2023-10-02 2025-04-09 Duke Street Bio Ltd PARP1 inhibitor compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942163A (en) 1989-03-07 1990-07-17 E. I. Du Pont De Nemours And Company 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents
EP1009404A4 (de) 1997-05-13 2009-07-01 Octamer Inc METHODEN ZUR BEHANDLUNG VON ENTZÜNDUNGEN ODER INFLAMMATIONS ERKRANKUNGEN DURCH INHIBITOREN DER pADPRT
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US20040176361A1 (en) * 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
WO2005075432A1 (ja) * 2004-02-06 2005-08-18 Chugai Seiyaku Kabushiki Kaisha 1−(2h)−イソキノロン誘導体およびその抗ガン剤としての使用

Also Published As

Publication number Publication date
JP4938311B2 (ja) 2012-05-23
EP1724262A4 (de) 2009-10-21
EP1724262A1 (de) 2006-11-22
WO2005075431A1 (ja) 2005-08-18
EP1724262B1 (de) 2012-05-02
US20070185160A1 (en) 2007-08-09
TW200536830A (en) 2005-11-16
JPWO2005075431A1 (ja) 2007-10-11
US8143274B2 (en) 2012-03-27

Similar Documents

Publication Publication Date Title
EP1724262A4 (de) 1-(2h)-isochinolonderivat
EA200601235A1 (ru) Производные тиазола
PT1261602E (pt) Derivados imidazol-2-carboxamida como inibidores de cinase raf
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
WO2008114817A1 (ja) 新規なアデニン化合物
WO2008114819A1 (ja) 新規アデニン化合物
WO2008108386A1 (ja) 医薬組成物
SE0400284D0 (sv) Novel compounds
CY1114767T1 (el) Ν,ν-υποκατεστημενες ενωσεις 3-αμινοπυρρολιδινης χρησιμες ως αναστολεις επαναπροσληψης μονοαμινων
ATE532770T1 (de) Imidazolderivat
NO20075734L (no) Tiofenforbindelser og trombopoietin reseptoractivatorer
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
NO20064297L (no) Aminoalkoholforbindelse
EP1634874A4 (de) Imidazolidinderivate
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
EP1775289A4 (de) Neue imidazolidinderivate
EA200701035A1 (ru) Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения
TW200517387A (en) Compounds exhibiting thrombopoietin receptor agonism
EA200700997A1 (ru) 2,5- и 2,6-дизамещенные аналоги бензазола, полезные в качестве ингибиторов протеинкиназ
WO2004091627A3 (en) Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs
NO20071230L (no) Oksazolidinoner inneholdende oksindoler som antibakterielle midler
EA200600551A1 (ru) Соединения пиперазина, способ их получения и фармацевтические композиции, которые их содержат
EA200901085A1 (ru) Производные циклогексиламида арилкарбоновой кислоты
FI20022159A0 (fi) Uusia farmaseuttisia yhdisteitä
EA200500716A1 (ru) Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат